IMF Annual Report 2021

Improving Lives Finding the Cure

®

COVER STORY

Yelak Biru

Leading the Way in the Fight Against Myeloma The 26-year myeloma survivor and advocate has been named as the International Myeloma Foundation’s new President & CEO. PAGE 6

2021 ANNUAL REPORT 1

INTERNATIONAL MYELOMA FOUNDATION RESEARCH | GLOBAL OUTREACH | EMPOWERING PATIENTS | TAKING ACTION

Improving Lives Finding the Cure

®

2021 ANNUAL REPORT

FISCAL YEAR OCTOBER 1, 2020 – SEPTEMBER 30, 2021

TABLE OF CONTENTS MESSAGE FROM THE CHAIRMAN OF THE BOARD

4

MESSAGE FROM THE PRESIDENT & CEO

5

COVER STORY

6

RESEARCH GLOBAL OUTREACH

8-12 13

EMPOWERING PATIENTS

14-16

TAKE ACTION/WAYS TO GIVE

17-20

FINANCIAL SUMMARY

21-23

A MESSAGE FROM THE CHAIRMAN OF THE BOARD

Dr. Brian G.M. Durie

Dear Friends, Yet again, it is hard to believe that a full year has been consumed by the COVID-19 pandemic.

Despite the challenges, the International Myeloma Foundation has been hugely successful in reaching out to the myeloma community through unique educational and support programs, as well as myeloma expert collaborations and ongoing clinical and laboratory research.

We appreciate and thank most sincerely all who have contributed to the remarkable success and progress of the IMF amid a year of global setbacks.

Providing education and support to keep myeloma patients safe from COVID-19 has been the focus of the IMF’s many initiatives. A special COVID-19 page was created on the IMF’s website; blogs and webinars highlighted key measures to stay safe, including getting vaccinated and boosted, using the right masks, and other necessary measures in situations of concern or where there is an increased risk.

At the 2021 ASH Annual Meeting in Atlanta, six abstracts from the research were presented with four as oral presentations. Preliminary data suggest that this type of early screening will, indeed, lead to improved outcomes, including the detection of undiagnosed smoldering myeloma with the potential for decisive early intervention. In 2022, the results of the largest randomized myeloma trial ever conducted will become available. Early screening could become the new standard of care.

As always, our top priority is the well-being of myeloma patients everywhere. The IMF works every day to bring the myeloma community together to fight myeloma while keeping myeloma patients as safe as possible.

Many patients were able to take advantage of Zoom calls and webinar programs, with numbers ranging from several hundreds to a few thousands on some key updates. However, it is not possible to compare the impact of in-person meetings with virtual programs.

We have also developed programs that foster resilience to sustain our energies to get us through these difficult times.

In addition, important myeloma research continued. The landmark ASCENT trial—where patients with high-risk smoldering myeloma (the earliest active disease with the best chance of achieving a cure) were treated with a decisive four-drug combination of best available drugs—completed accrual. We are awaiting longer-term results. The first patient for the trial achieved a fantastic response and is now MRDnegative after three years, with one year fully off any therapy. The initial trial results will be presented at the 2022 ASCO Annual Meeting.

Sincerely yours,

Another great success was the Black Swan Research Initiative®supported iStopMM® study. This study has over 80,000 participants from Iceland who have been screened to assess for the presence of early myeloma disease, such as MGUS or smoldering myeloma.

4

Thanks to all our supporters for remaining with us in 2021, as they have in the past. For our part, the IMF will be resilient and unflagging in striving to achieve the best outcomes for all myeloma patients.

Brian G.M. Durie, MD Chairman, IMF Board of Directors

A MESSAGE FROM THE PRESIDENT & CEO

Yelak Biru

Dear Friends, Another year has passed, and yet we are still in the midst of a pandemic.

Despite all the challenges, the International Myeloma Foundation has remained hopeful, resilient, and steadfast in its mission: to improve the quality of lives of myeloma patients while working toward prevention and a cure.

For more than 30 years, the IMF has been a catalyst for research, an accelerator of hope, and a partner to patients and their loved ones.

As a 26-year myeloma patient and long-time advocate for the prevention and cure of myeloma, I am humbled to join the organization as its new IMF President & CEO. I am grateful to be able to do what I am truly passionate about, in the service of those who love what we do.

I look forward to leading the very organization I turned to for guidance all these years and I sincerely thank the IMF for giving me this opportunity.

With your help and support, the IMF promises to continue to put myeloma patients at the center of everything we do—whether in research, education, support, or advocacy.

Our commitment to improving lives and finding a cure will never waver. We will always be here for you, and we are truly thankful to you for remaining by our side, especially during these challenging times.

Sincerely yours,

Yelak Biru IMF President & CEO

5

COVER STORY

International Myeloma Foundation Names Yelak Biru as President & CEO

New IMF President & CEO Yelak Biru speaking at the 2018 GMAN Summit Plenary Sessions in Stockholm, Sweden. Yelak was named Chief Executive Officer by the International Myeloma Foundation on November 15, 2021, and subsequently, as IMF President & CEO.

On November 15, 2021, Yelak Biru was named Chief Executive Officer by the International Myeloma Foundation. Subsequently, Yelak became the President & CEO of the organization.

Born in Ethiopia, the 51-year-old Yelak earned undergraduate and graduate degrees in computer science from the University of North Texas. After graduating, Yelak worked in advanced business analytics at PepsiCo until 2017, then joined Walmart to work in global technology, focusing on talent management practices, strategic direction, and associate engagement.

At age 25, while studying at the University of North Texas, Yelak was diagnosed with multiple myeloma. Driven to learn more about the disease, Yelak became an active participant in local myeloma patient support groups and eventually became one of their prominent leaders—first in Texas, then in Arkansas.

Yelak has been a member of the IMF Board of Directors since 2015, and has participated in the National Institutes of Health (NIH) Council of Research Advocates and the National Cancer Institute (NCI) Myeloma Steering Committee. He has also co-authored articles published in the Journal of the National Comprehensive Cancer Network and Blood Cancer Discovery and appears frequently at international medical conferences.

“Living with myeloma is not easy but having an organization like the IMF beside me during my cancer journey has helped me live with— and not for—myeloma,” Yelak attests.

“With the development of so many new treatments over the past 20 years, patients can reimagine living with myeloma. That’s why it’s so important for an organization like the IMF to put patients at the center of research, education, support, and advocacy,” said Yelak. He looks forward to leading the very organization he once turned to for guidance.

The IMF Board of Directors search committee selected Yelak because “he is a dedicated and visionary leader with an incredible depth and breadth of experience in the field,” according to Mayo Clinic Myeloma Specialist Dr. S. Vincent Rajkumar, who led the committee. The search committee attributes Yelak’s personal experiences as a myeloma patient and his proven track record and expertise in the corporate world.

“Yelak will provide inspirational leadership in the pursuit of our vision to cure myeloma,” Dr. Rajkumar further said.

IMF Founder and Director of Global Patient Initiatives Susie Durie, who 6

led the organization for 31 years, is “confident that Yelak will put his talent and experience as a patient advocate to good use in leading the organization I founded, nurtured, grew, and love so much.”

Yelak joins the IMF just as the Black Swan Research Initiative®—the IMF’s signature research project dedicated to finding a cure—had a breakthrough. Six abstracts from the IMF-funded iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study were presented at the American Society of Hematology (ASH) Annual Meeting in December 2021.

“Living with myeloma is not easy but having an organization like the IMF beside me during my cancer journey has helped me live with— and not for—myeloma.”

YELAK BIRU “Between the iStopMM study and the International Myeloma Working Group-developed Virtual Biobank project, we are expanding our knowledge of myeloma in a way that will impact diagnosis and treatment in the near future. I look forward to working with Yelak to move these efforts continually forward,” said IMF Chairman of the Board and co-founder, Dr. Brian G.M. Durie.

Global collaborations like the International Myeloma Working Group (IMWG) of top cancer researchers and the many IMF research partnerships in Asia, are “the cornerstone of the organization’s success,” said Yelak.

The African American community is another focus for the foundation, according to Yelak. “COVID-19, race relations, and social unrest over the last 18 months have amplified the need for improving access and outcomes in minorities and underserved communities,” he asserted.

To address that need, the IMF has launched a multidisciplinary initiative called M-Power. “The goal of M-Power echoes the core mission of the organization—to empower people to change the course of the disease by removing barriers to early diagnosis and treatment,” noted Yelak.

“For more than 30 years, the IMF has been a catalyst for research, an accelerator of hope, and a partner to patients and their loved ones. I am humbled by being asked to join the organization, and to do what I am passionate about doing, in the service of those who love what we do,” said Yelak.

IMF Board of Directors Brian G. M. Durie, MD

Chairman of the Board and Chief Scientific Officer, Professor of Medicine, and Hematologist/Oncologist – Los Angeles, CA

Yelak Biru

Christine Battistini

President of International Myeloma Foundation Latin America and Instituto Espaço de Vida – São Paulo, Brazil

Mario Boccadoro, MD

President & Chief Executive Officer

Professor of Medicine , University of Torino Torino, Italy

Susie Durie

Loraine Boyle

Writer/Producer – New York, NY

Founder & Director of Global Patient Initiatives International Myeloma Foundation Los Angeles, CA

Martine Elias, MSc

Executive Director Myeloma Canada – Quebec

Jason Katz

Charles Newman, MS

Marketing Executive & Technologist New York, NY

Entrepreneur – Ann Arbor, MI

S. Vincent Rajkumar, MD

Benson Klein, JD

Attorney – Bethesda, MD

Professor of Medicine Mayo Clinic – Rochester, MN

Andrew Kuzneski, III

Matthew Robinson, MBA

Investment and Banking – Indiana, PA

Robert A. Kyle, MD

Owner/General Manager Swift House Inn – Middlebury, VT

Professor Heinz Ludwig, MD

Communication Strategist – Philadelphia, PA

Professor of Medicine – Hematologist/ Oncologist , Mayo Clinic – Rochester, MN

George T. Hayum

Professor of Medicine, Wilhelminen Cancer Research Institute – Vienna, Austria

Entertainment Law – Los Angeles, CA

Edith P. Mitchell, MD

Professor of Medicine – Philadelphia, PA

IMF Executive Team Yelak Biru

President & Chief Executive Officer

Brian G.M. Durie, MD

Chairman of the Board and Chief Scientific Officer, Professor of Medicine, and Hematologist/Oncologist

Susie Durie Founder & Director, Global Patient Initiatives

Jennifer Scarne

Diane Moran

Lynn K. Green, Ed.D.

Senior Vice President, Strategic Planning

Senior Vice President, Philanthropy

Lisa Paik

Mimi Choon-Quinones, PhD, MBA Senior Vice President, Global Advocacy, Access, Policy & Research

Executive Vice President, Medical Affairs

Daniel Navid

Peter Anton

Senior Vice President, Global Affairs

Vice President, Marketing

Joseph Mikhael, MD

Robin Tuohy

Chief Medical Officer

Chief Financial Officer

E. Michael D. Scott

Vice President, Support Groups

IMF Staff Betty Arevalo

Heather Fishman

Marya Kazakova

Jason London

Miko Santos

Suzanne Battaglia

Jon Fitzpatrick

Ilana Kenville

Jim Needham

Kelley Sidorowicz

Missy Klepetar

Meghan O’Connor

Inventory Control Manager Senior Director, Member Events

Nancy Bruno

Donor Relations

Support Group Technology and Coordinator

Regional Director, Support Groups

Sherrie Guerrero

Kelly Cox

Abigail Guzman

Director, Human Resources

Director, Support Groups & Senior Meeting Registration & Director, Regional Community Guest Relations Workshops

Danielle Doheny

Director, Public Policy & Advocacy

Serdar Erdoğan

Director, GMAN and European & Middle Eastern Patient Programs

Brenda Hawkes

Director, Development

Paul Hewitt

Editor-in-Chief, Publications

Assistant Director, Member Events Publication Design InfoLine Coordinator

Phil Lange Accountant

Karla Lemus

Assistant to the Senior Director, Member Events

Robin Levy

InfoLine Coordinator

Senior Director, Public Policy & Advocacy

Kevin Huynh

Amirah Limayo

Web Specialist

Associate, Marcom & Web

Senior Research Project Coordinator

Web Producer

Regional Director, Support Groups

Meeting & Program Coordinator

Sarah Solomon

Matthew Ohnsman

Brando Sordoni

Audio Visual Project Coordinator

Selma Plascencia

Donor Relations

Accounting & Distribution

Rafi Stephan

Director, Operations

Assistant to the President & Chief Executive Officer

Annabel Reardon

Judy Webb

Senior Director, Strategic Program Management

Joy Riznikove

Database Analyst

InfoLine Coordinator

Jonathan Weitz Donor Relations

In early 2020, the IMF team met in Los Angeles for an annual retreat to plan for the coming year.

7

RESEARCH

Hopeful smiles from the members of the iStopMM team, an IMF-supported study based in Iceland. iStopMM is shedding light on the early development of myeloma by examining the potential benefits of early screening for MGUS, the precursor to myeloma.

UPDATE ON THE IMF’S BLACK SWAN RESEARCH INITIATIVE’S ISTOPMM PROJECT

The Black Swan Research Initiative® (BSRI) continues to make major strides with its iStopMM Project (Iceland Screens, Treats, or Prevents Multiple Myeloma). One of the largest studies ever conducted, the iStopMM Project has a record-setting 80,759 participants—the highest clinical participation ever for a single country.

The iStopMM study is the first of its kind to evaluate the benefits and harms of screening for patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma in which an abnormal protein appears in the blood.

A Paradigm Shift in Myeloma Therapy Published in Blood Cancer Journal in May 2021, the BSRI’s iStopMM Project could lead to a paradigm shift in myeloma therapy toward screening for the precursor of the disease and early treatment.

“Understanding the epidemiologic, genetic, and immunologic factors that go along with an increased risk of myeloma’s progression could open the door to early intervention efforts in high-risk patients and possible preventive strategies. This would improve overall survival and quality of life for patients worldwide,” states the study’s principal investigator, Dr. Sigurdur Kristinsson of the University of Iceland.

8

Oral Presentations from the iStopMM Study Take Center Stage at the 2021 ASH Annual Meeting Four oral presentations containing data from the iStopMM Project were showcased at the 63rd American Society of Hematology (ASH) Annual Meeting, which was held in Atlanta, GA from December 11-14, 2021.

“These are the very first presentations to come out of the iStopMM study and it is extremely encouraging for us that they are so well-received, highlighting [their] relevance and importance,” says Dr. Kristinsson.

The four iStopMM abstracts investigated: • The impact of very early screening for MGUS and early intervention in smoldering multiple myeloma (SMM) • The understanding of when to initiate treatment at the SMM stage • The risk of COVID-19 in MGUS • New testing that could lead to a more accurate diagnosis of monoclonal disease in those with kidney dysfunction

OTHER KEY BSRI PROJECTS IN 2021 The BSRI has over 50 ongoing projects worldwide. Here are some highlights: • A BSRI team in Nantes, France, is studying the specificity of monoclonal protein. The preliminary results show that these proteins’ antibodies work against a range of infections, including Hepatitis C, H. pylori, and others. BSRI researchers are seeing what happens to the myeloma protein when you treat these infections.

• The Spanish team, Drs. Alberto Orfao, Bruno Paiva, Jesús San Miguel, and María V. Mateos have developed and refined minimal residual disease (MRD) testing using next-generation flow. Today, the team is using mass spectrometry to detect very low levels of myeloma protein. The team has learned that there is a subset of patients who are MRD-negative and also negative with mass spectrometry; and also, another subset of patients who are MRD-negative, but are MRD-positive when detected by mass spectrometry. The BSRI team is working to follow up with these patients on a longer term to better understand low-level indolent disease versus those who are truly MRD-negative.

• The BSRI is also doing retrospective studies. For example, the team is looking at the immunology and molecular features of long-term survivors (20 years or more).

• A next opportunity is to try to achieve MRD undetected at biochemical relapse. This BSRI concept has been introduced to patients with either persistent or recurrent MRD positivity.

A NOTE ON THE IMF’S VIRTUAL BIOBANK AND IMMUNE THERAPY REGISTRY The Virtual Biobank The International Myeloma Working Group (IMWG) is currently developing a virtual biobank. Tissue samples (such as bone marrow and blood samples) are collected from patients undergoing treatment, particularly the newer immune therapy treatments, to better understand the mechanisms of why some patients respond while others do not.

In a virtual biobank, all samples are collected, kept, and tested in a local setting with the results entered into a computer and submitted electronically for storage and analysis. This makes the process more efficient and attractive to investigators because they have control over their samples and can conduct testing that is of great interest to their patient population.

The Immune Therapy Registry Through the efforts of investigators Dr. Thomas Martin (UCSF Helen Diller Family Comprehensive Cancer Center—San Francisco, CA) and Dr. Yi Lin (Mayo Clinic—Rochester, MN), the IMWG has started an immune therapy registry.

The immune therapy registry will be electronically housed at the University of California, San Francisco and will serve as a valuable resource of important real-world data for patients, investigators, and pharma partners around the globe to gain a better understanding of how the different therapies work or what the best sequencing of drugs might be.

Some members of the iStopMM team at the IMWG Breakfast during the ASH Annual Meeting.

SOME HIGHLIGHTS OF BSRI PUBLICATIONS FROM FISCAL YEAR 2021 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma Puig N, Flores-Montero J, Burgos L, et al. Cancers (Basel). 2021 Sep 30;13(19):4924.

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of followup strategies Rögnvaldsson S, Love TJ, Thorsteinsdottir S, et al. Blood Cancer J. 2021 May 17;11(5):94.

Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma Carrasco-Leon A, Ezponda T, Meydan C, et al. Leukemia. 2021 May;35(5):1438-1450.

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients Mendonca de Pontes R, Flores-Montero J, Sanoja-Flores L, et al. Cancers (Basel). 2021 Apr 3;13(7):1704.

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Damasceno D, Almeida J, Teodosio C, et al. Cancers (Basel). 2021 Mar

22;13(6):1454.

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis Palladini G, Paiva B, Wechalekar A, et al. Blood Cancer J. 2021 Feb 16;11(2):34.

Characterization of rare germline variants in familial multiple myeloma Catalano C, Paramasivam N, Blocka J, et al. Blood Cancer J. 2021 Feb 13;11(2):33.

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma Goicoechea I, Puig N, Cedena MT, et al. Blood. 2021 Jan 7;137(1):49-60.

9

RESEARCH INTERNATIONAL MYELOMA WORKING GROUP’S MILESTONES IN 2021 The IMF hosted the 12th Annual International Myeloma Working Group (IMWG) Summit virtually from June 22-23, 2021. Held online for the second year in a row, the Summit convened the world’s top myeloma experts. Its mission is to identify, support, and implement the most promising research to prevent the onset of active disease, to improve treatment, and to find a cure.

Dr. Shaji Kumar (Mayo Clinic—Rochester, MN) led the first session, a discussion of the 2/20/20 risk stratification model for highrisk smoldering multiple myeloma (HR SMM). This important advancement was developed as a result of an IMWG research project and published in Blood Cancer Journal in October 2020. Data was gathered from a large number of international sites to assess which patients with SMM had progressed, and which patients had not. The 2/20/20 system was devised in a collaboration between Dr. Kumar and Dr. Durie with the Spanish team led by Dr. Jesús San Miguel (Clinica Universidad de Navarra—Navarra, Spain) and Dr. MaríaVictoria Mateos (University of Salamanca—Salamanca, Spain).

• • • •

The development of a Virtual Tissue Bank as part of the Asian Myeloma Network’s initiatives The use of mass spectrometry to detect monoclonal proteins at a very early point A keynote lecture on the role of COVID-19 vaccination and myeloma patients A discussion of disparities in clinical trials access and accruals

By any measure, the 2021 IMWG Summit was a wonderfully successful and productive event, with lively interactions among participants who took full advantage of the opportunities to make plans for future research collaborations.

The IMWG also developed a point-scoring system and an online calculator app to identify ultra-high-risk SMM—a group for which immediate treatment can be strongly considered. Patients who score 12 or more points have ultra-high-risk SMM and are eligible for treatment.

Other highlights of the Summit included the presentation of the IMF’s 20th Annual Robert A. Kyle Lifetime Achievement Award to Dr. Nikhil Munshi, the Kraft Family Chair and Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, and the Associate Director of the Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute in Boston, MA. This award honors an individual whose body of work has made significant contributions to myeloma research and patient care.

The Brian G.M. Durie Outstanding Achievement Award, recognizing excellence in myeloma research, was awarded to Dr. Shaji Kumar, a consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, MN. Dr. Kumar is also the Chair of the Myeloma, Amyloidosis, and Dysproteinemia Group, and an Associate Chair for research in the Department of Medicine at Mayo Clinic.

As is tradition with the Summit, the myeloma experts broke out into working group committees and discussed the following topics: • Current data on high-risk smoldering multiple myeloma treatment • Four-drug (quadruplet) vs. three-drug (triplet) therapies • The potential standardization of minimal residual disease in clinical trials • Current and next-generation CAR T-cell and other cellular therapies, such as bispecifics • A report on the IMWG Immune Therapy Committee, which has established a framework for a new registry to be housed at University of California, San Francisco

10

A VIRTUAL GATHERING. IMF Chairman of the Board Dr. Brian G.M. Durie and the world’s top myeloma experts convened virtually for the 12th Annual International Myeloma Working Group (IMWG) Summit from June 22-23, 2021.

IMWG PUBLICATIONS Moreau P, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology 2021; 22: e105–18.

Murray D, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.

Blood Cancer J. 2021 Feb 1;11(2):24.

Terpos E, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology 2021.

The Asian Myeloma Network team at work during the AMN Summit.

FOURTH ANNUAL IMF ASIAN MYELOMA NETWORK SUMMIT The 4th Annual IMF Asian Myeloma Network (AMN) Summit was held from October 17–18, 2020. The event was originally scheduled to be in-person in Singapore but became a virtual two-day gathering instead, due to COVID-19.

The AMN Summit is an annual gathering of leading myeloma specialists in Asia where the latest developments in myeloma diagnosis and treatment are shared, and discussions on priorities for action in the coming year are held in a workshop setting.

Because in-person participation was not permissible, government regulations made accommodations to organize AMN “studios” in several major cities. Arrangements were made with the hub of the Summit in Bangkok and satellite studios were set up in Beijing, Seoul, Shanghai, and Singapore. This allowed AMN members to converge locally and to participate in the Summit.

AMN members and industry observers were also able to participate online from China, Hong Kong, Japan, Korea, Malaysia, Singapore, Taiwan, and Thailand.

In the U.S., Dr. Brian G.M. Durie (IMF Chairman of the Board) and his staff were able to join in from the IMF headquarters in Los Angeles.

Myeloma experts Drs. S. Vincent Rajkumar (Mayo Clinic—Rochester, MN) and Thomas Martin (UCSF Helen Diller Family Comprehensive Cancer Center—San Francisco, CA) participated from other locations.

European myeloma experts Drs. Jean-Luc Harousseau (University of Nantes—Nantes, France), Alberto Orfao (University of Salamanca— Salamanca, Spain), and Stephen Harding (The Binding Site— Birmingham, West Midlands, UK) made contributions via recorded video.

On Day 1, Frontline Therapy, Minimal Residual Disease (MRD), Immune Therapies, and Relapsed Myeloma were topics covered, with global perspectives presented by Dr. Rajkumar, Dr. Orfao, Dr. Martin, and Dr. Harousseau. Asian perspectives were presented by Dr. Wee Joo Chng (Singapore), Dr. Wenming Chen and Dr. Juan Du

(China), and Dr. Kihyun Kim (South Korea), respectively. Q&A panel discussions from AMN members followed the presentations.

Day 2 kicked off with reports made by the AMN Standing Committees on a virtual tissue bank (Dr. Chng and Dr. JH Lee of Korea); high-risk myeloma treatment (Dr. Chim of Hong Kong and Dr. Huang of Taiwan); the establishment of an AMN MRD sub-committee (Dr. Chuncharunee of Thailand and Dr. Chen); CAR T-cell clinical trials in Asia (Dr. Du and Dr. Martin); and Asian patient support (Dr. Tan of Singapore and Dr. Shimizu of Japan).

AMN members agreed to set up a virtual AMN Tissue Bank Project, to prepare clinical trial proposals for high-risk myeloma patients, to create an MRD program (including training for AMN centers), to pursue CAR T-cell and other immune therapy clinical trial projects, and to move ahead with a patient support program for each AMN country and region.

An update on ongoing AMN clinical trials and a discussion about future initiatives were also provided by Dr. Chng, followed by a review of algorithms for the treatment of myeloma. Dr. Rajkumar gave a global overview while Dr. Tan provided an Asian perspective.

Headed by Dr. Durie and Dr. Rajkumar, the final session of the AMN Summit focused on strategies for disease management and was especially lively, with guidance provided by the global IMF experts.

UPDATE ON AMN CLINICAL TRIALS The IMF carries out innovative clinical trials throughout Asia via the AMN. Valuable research data and access to novel therapies have become readily available to Asian myeloma patients because of these efforts.

• AMN001 in 2019 was an access program with 136 relapsed myeloma patient participants who were previously exposed to bortezomib and lenalidomide and who were later treated 11

RESEARCH

2021 BRIAN D. NOVIS RESEARCH GRANT AWARDS The International Myeloma Foundation (IMF) presented its 2021 Research Grant awards in December 2020 via a virtual ceremony with IMF Chairman of the Board Brian G.M. Durie, MD and IMF Founder Susie Durie.

JUNIOR GRANT RECIPIENT

Junior Research Grant projects are funded at $50,000.

EUGENIO MORELLI, MD

Dana-Farber Cancer Institute, Boston, MA, USA Characterization of RROL-driven Lipogenic Signaling in Multiple Myeloma Cells Funded by the 8th Annual Miracles for Myeloma 5K Participants at the Asian Myeloma Network Summit.

...Continued from Page 11

•

•

•

•

•

12

with pomalidomide (pom) and dexamethasone (dex). The data demonstrated high response rates. The findings were published in Blood Cancer Journal.

AMN002 in 2020 was a randomized phase II study that utilized different doses of carfilzomib with cyclophosphamide and dex for relapsed/refractory myeloma patients previously exposed to bortezomib. 41 patients in Asia and 50 patients in Australia and New Zealand participated in the study.

AMN003 is an ongoing randomized phase III study involving 120 patients in Asia comparing the combination of pom, cyclophosphamide, and dex to the combination of pom and dex in relapsed or refractory myeloma patients.

AMN004 was a phase II study with 70 patient participants in Asia. Completed in April 2021, it examined the use of daratumumab (dara) in combination with thalidomide and dex in patients with relapsed and/or refractory myeloma.

AMN006 was a phase II study completed in September 2021, involving the use of dara in combination with bortezomib and dex in newly diagnosed, transplant-ineligible patients.

Originally intended to involve 63 patients, participants were reduced to 30 in May 2021.

Several additional AMN clinical trial projects are currently being negotiated with implementation beginning in 2022.

Characterization of RROL-driven Lipogenic Signaling in Multiple Myeloma Cells

Cellular RNA can serve as a precursor for proteins or as an effector molecule with an active role in malignant transformation. We have discovered an RNA molecule (RROL) promoting the synthesis of lipids in multiple myeloma (MM) cells; these lipids can, in turn, be used as energy storage, for the synthesis of cellular membranes or to regulate the molecular signaling. We hypothesize that, in doing so, RROL cooperate with oncogenic proteins forming a novel discovered RNA‐ protein complex. We propose to investigate the molecular mechanism of RROL to inform the development of clinically applicable novel therapeutic approaches for translation to clinical trials.

ABOUT EUGENIO MORELLI, MD Dr. Morelli is a postdoctoral fellow at Dana-Farber Cancer Institute and Harvard Medical School (Boston, MA, USA). He earned his MD in 2011 from Magna Graecia University of Catanzaro (Catanzaro, Italy) and completed a clinical/research fellowship in Medical Oncology at the same University. During his fellowship, Dr. Morelli gained expertise in molecular biology and experimental therapeutics of multiple myeloma. Under the mentorship of Dr. Pierfrancesco Tassone, he primarily focused on the biologic role and therapeutic implications of small noncoding RNAs (i.e. microRNAs) in multiple myeloma, pioneering the use of primary miRNA (pri-miRNA) therapeutics of human cancer. Dr. Morelli joined Dr. Nikhil Munshi’s Lab at Dana-Farber Cancer Institute in 2017 as a post-doctoral fellow. Since then, he has focused his research to systematically map, functionally characterize and therapeutically target long noncoding RNA (lncRNA) dependencies in multiple myeloma. His work has led to discover the novel lncRNA RNA Regulator of Lipogenesis (RROL) with critical role in driving the malignant phenotype of myeloma cells. The Brian D. Novis Junior Award will enable Dr. Morelli to decode the molecular mechanism and biologic role of RROL in multiple myeloma; and to develop strategies to therapeutically target this lncRNA for translational to clinical trials. Dr. Morelli found the perfect environment in the Munshi Lab to pursue his scientific interests, and this Award will provide a significant boost to a rapid translation of his findings to the clinical setting to improve the outcome for myeloma patients.

GLOBAL OUTREACH

ALL HANDS ON DECK. The annual GMAN Summit was held virtually from August 25–26, 2021, with 50 advocates from 5 continents and 30 countries in attendance.

IMF’S GLOBAL MYELOMA ACTION NETWORK: ACTIVITIES IN EUROPE AND BEYOND

The IMF’s Global Myeloma Action Network (GMAN) brings together advocacy leaders in multiple myeloma to improve the lives of myeloma patients around the world.

• In fiscal year 2021, GMAN held a virtual meeting at the American Society of Hematology (ASH) Annual Meeting. In attendance were participants from countries and regions in Europe, Australia, Canada, Latin America, and the United States, as well as GMAN’s industry partners.

GMAN members gained knowledge about the latest advances in myeloma and engaged with disease experts. Of note were hybrid and virtual Patient Webinars that reported on best practices as well as Turkey’s pandemic project for myeloma patients.

•

• In March 2021, GMAN members celebrated Myeloma Action Month (MAM) digitally through social media and online seminars.

Online seminars and webinars were conducted for myeloma patients in Colombia, Hong Kong, Iceland, IMF Latin America, Italy, South Korea, and Turkey with more than 6,000 attendees participating globally.

MAM graphs of “31 Days of Resilience” and “Myeloma Facts” were translated into several languages: Czech, French, German, Italian, Korean, Portuguese, Russian, Spanish, and Turkish.

The annual GMAN Summit was held virtually from August 25–26, 2021, with 50 advocates from 5 continents and 30 countries in attendance. Serdar Erdoğan, IMF’s Director of GMAN, Europe & Middle East Patient Programs, opened with a summary of IMF and GMAN’s digital efforts and virtual events in the past year. Highlights of the virtual summit include: • Dr. Brian G.M. Durie (IMF Chairman of the Board) talked about “New and Emerging Treatments in MM,” which included informa-

tion about CAR T-cell therapies and bispecifics as well as current treatment and trial updates. He also highlighted important updates about COVID-19 in relation to myeloma.

Susie Novis Durie (IMF Founder and Director of Global Patient Initiatives) and Robin Tuohy (IMF Vice President, Support Groups) shared their experiences for caregivers, focusing on difficulties brought about by the pandemic. They also provided information on virtual support groups as well as special-focus support groups as possible options that can be explored in other countries.

Dr. Sigurdur Kristinsson provided updates about the iStopMM Project, highlighting exciting results about the impact of screening for MGUS. Mimi Choon-Quinones (IMF Senior Vice President, Global Advocacy, Access, Policy & Research) gave an update on the IMF’s Beyond Medicines’ Barriers (BMB) program while emphasizing several projects.

The panel discussion on “How Can We Improve Access to Trials for MM Patients?” was held with Dr. Brian Durie, Dr. Daryl Tan, Dr. Jean-Luc Harousseau, and Dr. Hartmut Goldschmidt in attendance. All agreed that identifying a “champion” is extremely important in smaller countries, if they are able to participate in trials.

One of the biggest highlights of the Summit was naming the recipients of the 2021 Susie Novis Durie Grant. This year the 2021 grants were announced for 4 countries: Austria’s “Home Training Exercise Program,” Croatia’s “Pathway to Clinical Trials in South Eastern Europe,” Israel’s “Raise Awareness Among Arabic Population,” and Portugal’s “Website Providing Professional Answers.”

13

EMPOWERING PATIENTS

34

14

WEBINARS

2,000 10,000 +

PROVIDED 550 VIRTUAL VISITS

AND OUTREACH

BENEFITING

FACILITATED

VIRTUAL

150+ TECH INSTRUCTION

112

SUPPORT

AND ONE-TO-ONE VIRTUAL MEETINGS

6,500+

14,000 3.1M REACHED

1.1 M REACHED

THROUGHOUT THE COVID-19 PANDEMIC, THE INFOLINE TEAM HAS RESPONDED TO

TO MORE THAN

6,000

CALLS AND EMAILS TO ADDRESS SPECIFIC

NEEDS OF MYELOMA PATIENTS ACROSS THE GLOBE

15

EMPOWERING PATIENTS

Posing for a group photo at the NLB annual meeting in 2019. The IMF Nurse Leadership Board is comprised of myeloma nursing experts from major centers that provide treatment for myeloma.

IMF NURSE LEADERSHIP BOARD ADAPTS IN FISCAL YEAR 2021

The IMF Nurse Leadership Board® (NLB) consists of nurse experts from leading medical centers who care for myeloma patients and who collaborate to improve their patients’ lives. Due to the pandemic, the NLB reimagined many programs in 2021 by adapting in-person events to virtual programming.

The NLB’s 2021 Oncology Nursing Society (ONS) Satellite Symposium, “Case Studies in Myeloma Care for Challenging Times,” took place online in April 2021. The distinguished NLB panel included NLB Chair Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; as well as NLB Faculty members Amy E. Pierre, RN, MSN, ANP-BC; Donna D. Catamero, ANP-BC, OCN, CCRC; and Charise Gleason, MSN, NP-BC, AOCNP®. They presented six HIPAA-compliant case studies, with each illustrating a myeloma patient at a specific stage of the disease.

This fiscal year, NLB members served as faculty at IMF education forums, including 4 Patient and Family Webinars, 10 IMF Regional Community Workshops, and 18 virtual support group presentations that reached over 14,000 participants. They also took part in the inaugural M-Power Community Workshops to tackle awareness of multiple myeloma risks and disparities among the African American communities of Charlotte, Baltimore, and Atlanta.

Additionally, the NLB participated at the Support Group Leaders

16

Summit, Support Group Leaders at ASH, and conducted numerous roundtables with both patients and professionals to fulfill their mission of improving care and quality of life for myeloma patients.

Last year, the nurses developed a popular treatment discussion tool.

Eight hundred printed copies have been distributed so far. It is also available for download online along with a companion explanatory video which has been viewed 500 times. This year, the NLB nurses are tackling a new tool for patients to facilitate difficult conversations about myeloma with their loved ones.

The NLB revealed their new patient education deck, “Life Is a Canvas, You Are the Artist,” at the 2021 August Patient and Family Webinar.

They participated in IMF educational video vignettes for patients which address newer treatment options and mechanisms of action, and they are making finishing touches on the first round of the Myeloma University video series which will be made available in 2022.

Finally, travel restrictions could not deter the important work of the NLB. At the 17th annual meeting that was held virtually in September, the NLB discussed addressing disparities, particularly regarding clinical trial enrollment. They also updated their educational case studies and worked on developing tools for both patients and nurses to provide valuable insights into treatment options among the relapsed/refractory patient population.

TAKE ACTION The COVID-19 pandemic also created much-needed public awareness about the vast health disparities in our nation. President Biden and Members of Congress recognized this issue and began to seriously discuss taking steps to address it. The IMF, in collaboration with various coalitions, has been working to advance bills addressing health disparities, particularly in clinical trials.

Robin Roland Levy, IMF Senior Director, Public Policy & Advocacy

Danielle Doheny, IMF Director, Public Policy & Advocacy

THE VOICE OF MYELOMA PATIENTS IN POLICYMAKING, RESEARCH FUNDING, AND LEGISLATION Throughout 2021, the IMF’s Advocacy Team continued to be an active voice for the myeloma patient, which included involvement in policymaking debates. We met with Congressional offices, sent letters to legislators, and worked as active members of coalitions to advance bills. Many of the issues we worked to address were related to the COVID-19 pandemic, ensuring that the myeloma patient’s voice was heard by legislators on important issues like telehealth and vaccine access.

One issue that remains particularly important, especially in light of the ongoing pandemic, is the issue of accessibility of oral anticancer medications. Oral parity legislation addresses this issue by ensuring that oral chemotherapy drugs, like many of the drugs taken by myeloma patients, are covered by insurers in the same way as IV therapies. The IMF previously worked to pass laws to ensure this equitability at the state level. Due to these efforts, 43 states along with Washington, D.C. have state-level laws addressing this issue. That said, federal legislation is still needed.

The IMF has been actively working to address the needs of those who do not benefit from state bills. On July 9, 2021, H.R. 4385 was reintroduced to the House of Representatives. This bill has bipartisan support and would help many of the individuals not reached by state-level laws already passed. Due to political issues, the bill had to be restructured slightly and the IMF led the efforts to rewrite the legislation and work with members of the Coalition to Improve Access to Cancer Care (CIACC) and Congressional leaders to ensure this process ran smoothly. The IMF has made it an even larger priority to advance the bill and has been strategizing, working with Congressional stakeholders, and aggressively pushing legislative efforts.

The IMF has also acted as active coalition members, who advocate for an increase in research funding. Particular efforts are being placed on the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP), and the U.S. Food & Drug Administration (FDA) to help continue scientific progress and to bring new therapies to patients more quickly.

VETERANS AGAINST MYELOMA (VAM) REPORT The IMF recognizes that veterans facing a myeloma diagnosis often have unique experiences and differing access issues compared to other patients. In 2021, the IMF’s Veterans Against Myeloma (VAM) program continued to focus on ensuring that policymakers are made aware of the needs of veterans to make sure that myeloma remains as a service-connected disease.

The IMF has long supported the inclusion of “blood cancers” as a topic area in the Congressionally Directed Medical Research Program (CDMRP)’s Peer Reviewed Cancer Research Program (PRCRP). This inclusion is important because it allows myeloma researchers to apply for grant funding through this program and allows the IMF to nominate myeloma patients to participate and engage in the program as consumer reviewers. These efforts require us to approach Congressional leaders and make the case for blood cancers.

Congress has been talking steadily about toxic exposures veterans have faced. Congressional leaders in both the House and the Senate have made it clear that they intend to address toxic exposure issues this Congressional term. They have been focusing steadily in building on the success of the Blue Water Navy Vietnam Veterans Act, a bill endorsed by the IMF. Many bills have already been introduced to help veterans who have been faced with toxic exposures. Hearings have been held surrounding this important matter. The IMF has been closely monitoring Congressional efforts to address toxic exposure issues. As these conversations progress, we will make sure that legislators will have the needs of veterans with myeloma represented.

17

TAKE ACTION

MEMBER FUNraisers COOKING FOR A CURE / MAY 23, 2021

LAUGHS 4 LIFE / JULY 30, 2021

HATFIELD HIKE / SUMMER 2021

Participants learned cooking skills from Chef Alonso Roche and prepared a meal together for them to enjoy following the cooking lesson.

This night of comedy featured Nate Bargatze and Leanne Morgan, and generated smiles and laughter throughout the wonderful Hub City community in Hattiesburg, MS.

Bill Hatfield, with his dog, Huckleberry, hiked the Appalachian Trail this past summer to raise awareness and donations for the IMF and another charity.

Organizer: Lori Klein

Organizer: Kent Oliver

Organizer: Bill Hatfield

#KNOWMYELOMA VARIETY SHOW / SEPTEMBER 30, 2021 This Twitch.TV livestream featured performers who have been affected in one way or another by myeloma, including internationally touring comedian Forrest Shaw, “Ologies” podcast host Alie Ward, Dance Theatre of Harlem ballerina Daphne Lee, LA-based writer and mom Jen Curran, and IMF Chief Medical Officer Dr. Joseph Mikhael.

Special Thanks to Josephine McAdam for hosting!

18

DONOR SPOTLIGHT KRISTI WILLETTE:

‘FIGHT THE FIGHT AND NEVER GIVE UP!’ Kristi Willette has had a long-term relationship with the International Myeloma Foundation—spanning more than twenty years.

It all began after her husband, Chick Willette, was diagnosed with myeloma in November 1999. The Willettes were referred by Chick’s attending physician, Dr. Louis Vandermolen of Hoag Hospital in Newport Beach, to IMF Chairman of the Board Dr. Brian G.M. Durie for a deeper assessment and for in-depth knowledge about the disease.

Dr. Vandermolen and Dr. Durie worked closely together in developing a treatment plan for Chick, allowing him to live for 13 years.

However, the Willettes’ relationship with the IMF would go beyond myeloma treatment and care. Kristi fondly recounted how, in subsequent years, she and her husband would cross paths with Dr. Durie and Susie Novis Durie at the Annual Comedy Celebration and how gracious the Duries had always been to her and Chick.

For several years, Chick was in remission but in 2009, Chick had a relapse.

They were again referred to Dr. Durie to consult for a possible new treatment or a trial study. One trial was enough for Kristi to be hopeful but instead, Dr. Durie provided them with five treatment options— recommending one in particular. Chick’s doctor administered the treatment plan recommended by Dr. Durie and Chick was able to live for three more years, traveling with his wife and enjoying life.

When Chick passed away in August 2012, he provided for a foundation in his trust. “In the years leading up to his diagnosis, we had talked about giving back in one form or another. Upon Chick’s passing, a notfor-profit trust was created. One area of focus would be cancer research leading to a cure for multiple myeloma,” Kristi recounted.

A year later, the Willette Charitable Foundation was established— inspired by Chick’s dignity, grace, and great fight against myeloma, and by the “genius and talent” of the medical professionals that the Willettes had gotten to know over the years. The Willette Charitable Foundation made its first donation to the IMF in December 2013.

“Our mission statement is to promote and support cancer research, treatment, care, and financial assistance,” said Kristi.

The Willettes’ remarkable relationship with the IMF has made Kristi especially interested in supporting the IMF’s endeavors—particularly in the field of research and the Black Swan Research Initiative®.

culturalization presents the perfect setting,” Kristi further added.

When asked about her interest in the IMF’s advocacy, webinars, new treatments, and International Myeloma Working Group’s (IMWG) guidelines, Kristi had this to say: “I have always been impressed with the work and reporting of the IMWG. I have been privileged to be an onlooker at these meetings.

These are my favorites of the ASH annual conference. Sitting on the sidelines and hearing a global effort to find the cure. Listening to the challenges each country faces and working together to overcome so many challenges can only be the road to success.”

“The IMF is unique in that they have reached out to all corners to share information, share a focused goal to eradicate this terrible disease. They have worked diligently with government agencies, pharmaceutical companies, scientists, investigators, donors, and corporate foundations to drive their mission. Their efforts continue to amaze me. I know their heart and their being is all about this pursuit: TO FIND A CURE!,” Kristi enthused.

“The Black Swan Research Initiative was so exciting when announced, as the word ‘cure’ was never in the same sentence as multiple myeloma.

We supported some truly wonderful research to put the IMF on the path to this enormous goal,” Kristi recalled.

In closing, Kristi shared some encouraging words for the myeloma community: “Never give up. The strides toward this goal have provided better ways to live with myeloma while the research is boldly in full swing. Finding the key to unlock the door to a cure is the IMF’s waking mission. Never give up on taking full advantage of all the IMF offers: education through Dr. Durie’s blogs, the continued reporting of advancements, and telephone support.”

“When the iStopMM® trial was presented, we split our efforts as it seemed to be a very viable avenue of research. When would this opportunity presented by Iceland ever exist again? Having an entire country involved in the search for a cure is the ideal setting! The country has a medical database for all citizens. The isolation of country and very limited cross-

“The IMF is there for you at every step. You only need to reach out. Fight the fight. Appreciate your caregivers. The IMF gives full support not only to their patients but to all those who support you in the fight against myeloma. You never have to feel you are alone. The IMF is there for you,” Kristi assured.

19

WAYS TO GIVE

ONE-TIME GIFTS:

MONTHLY GIFTS:

TRANSFORMATIONAL GIFTS:

PLANNED GIFTS:

LEGACY GIFTS:

STOCK GIFTS:

All amounts help—from $5 to $500. Visit donate.myeloma.org NOW!

Honor a loved one with a tribute gift, recognize a physician or nurse, support IMF research with a major gift. These gifts are integral to the success of the IMF. Contact Lynn Green, IMF Senior Vice President, Philanthropy, at lgreen@myeloma.org or 818-487-7455 x268.

Support the IMF’s mission of prevention and finding a cure for multiple myeloma through a gift in your will. The IMF has partnered with our friends at FreeWill (https://www.myeloma.org/freewill) to allow you to write a free, legal will online in less than 25 minutes. Save time and money while securing your legacy for the people and causes you love today.

20

Join the IMF’s Hope Society by making monthly gifts. Starting at $10 per month, you can support IMF core programs, including educational events, publications, the toll-free InfoLine, and more! New members can select a limited-edition Hope Society gift! Contact Jonathan Weitz, IMF Donor Relations, at 1-800-452-2873 ext. 254 or jweitz@myeloma.org to learn more.

Support the IMF and plan for your future through various planned giving options such as bequests and IRA contributions. These gifts are an excellent way to receive additional tax benefits. Contact Lynn Green, IMF Senior Vice President, Philanthropy, at lgreen@myeloma.org or 818-4877455 x268.

Donations of stock or other securities offer ideal opportunities to receive additional tax benefits through your philanthropic giving. Should you or your financial advisor have additional questions, please contact Lynn Green, IMF Senior Vice President, Philanthropy, at lgreen@myeloma.org or 818-487-7455 x268.

FINANCIAL SUMMARY

INTERNATIONAL MYELOMA FOUNDATION

Statement of Financial Position September 30, 2021 ASSETS CURRENT ASSETS

Cash and cash equivalents $ 4,933,768 Investments, at fair value 12,575,957 Contributions, program grants, and other receivables 1,156,224 Prepaid expenses 515,429 Total Current Assets

19,181,378

OTHER ASSETS

Property and equipment, net Intangible assets, net Security deposits

241,573 105,415 10,968

Total Other Assets

357,956 $

TOTAL ASSETS

19,539,334

LIABILITIES AND NET ASSETS LIABILITIES

Accounts payable and accrued expenses $ Deferred program and educational grants Refundable advances Gift annuity obligation

1,160,541 4,065,524 2,255,000 71,500 7,552,565

TOTAL LIABILITIES NET ASSETS

Without donor restrictions With donor restrictions

11,741,790 244,979

TOTAL NET ASSETS

11,986,769

TOTAL LIABILITIES AND NET ASSETS

$

19,539,334

For a copy of our complete audited financial statements, please contact the IMF office.

21

INTERNATIONAL MYELOMA FOUNDATION

Statement of Activities and Changes in Net Assets for the Year Ended September 30, 2021 With Donor Restrictions

Without Donor Restrictions

Total

REVENUES AND SUPPORT $ 7,428,870

$ 2,430,000

$ 9,858,870

General contributions

Educational and program grants

2,641,247

329,046

2,970,293

Clinical trials and research revenue

4,262,599

-

4,262,599

-

(4,574)

(4,574)

29,815

-

29,815

-

154,235

154,235

634,659

16,162

650,821

14,997,190

2,924,869

17,922,059

(7,812)

7,812

-

2,763,280

(2,763,280)

-

$ 17,752,658

$ 169,401

$ 17,922,059

13,512,687 655,289 1,115,813

-

13,512,687 655,289 1,115,813

$ 15,283,789

-

$ 15,283,789

CHANGE IN NET ASSETS

2,468,869

169,401

2,638,270

NET ASSETS - Beginning of year

9,272,921

75,578

9,348,499

$ 11,741,790

$ 244,979

$ 11,986,769

Change in split interest agreements Support group income Fundraising events, net of direct benefit to donors of $168,323 Investment income, net of fees $59,412

Transfer to annuity assets Net assets released from restrictions TOTAL REVENUES AND SUPPORT

FUNCTIONAL EXPENSES Program expenses General supporting expenses Fundraising TOTAL FUNCTIONAL EXPENSES

NET ASSETS - End of year

Revenue Breakdown* General Contributions 15%

All Other 4%

Expense Breakdown Fundraising 7% General Support Expenses 4%

Research 42% Education & Other Program Grants 39%

22

Program Expenses 89%

* Percentages based upon detailed final trial balance.

For a copy of our complete audited financial statements, please contact the IMF office.

INTERNATIONAL MYELOMA FOUNDATION

Statement of Functional Expenses for the Year Ended September 30, 2021 Breakdown of Expenses by Program PROGRAM

Research Education and Awareness Support Groups Patient and Family Seminars Advocacy International Nurse Website InfoLine Myeloma Today Clinical Meetings Information Mailings Total Program Expenses

TOTAL EXPENSES

$ 7,268,622 1,855,781 815,003 573,017 568,222 536,180 473,063 453,728 446,723 309,343 149,179 63,826 $ 13,512,687

Fundraising Expenses General Supporting Expenses Total Expenses

1,115,813 655,289 $ 15,283,789

For a copy of our complete audited financial statements, please contact the IMF office.

23

IMF International Headquarters 4400 Coldwater Canyon Avenue, Suite 300, Studio City, CA 91604, USA 1-800-452-2873 (U.S. & Canada) | 1-818-487-7455 (Worldwide) TheIMF@myeloma.org

myeloma.org